{"id":"gadoversetamide","rwe":[{"pmid":"30000471","year":"2006","title":"Gadoversetamide.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39135199","year":"2024","title":"Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.","finding":"","journal":"BMC medicine","studyType":"Clinical Study"},{"pmid":"38244800","year":"2024","title":"Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.","finding":"","journal":"Journal of affective disorders","studyType":"Clinical Study"},{"pmid":"37991701","year":"2024","title":"Gold nanoparticles conjugated with epidermal growth factor and gadolinium for precision delivery of contrast agents in magnetic resonance imaging.","finding":"","journal":"Radiological physics and technology","studyType":"Clinical Study"},{"pmid":"35184618","year":"2022","title":"Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes in vitro.","finding":"","journal":"Drug and chemical toxicology","studyType":"Clinical Study"}],"tags":[{"label":"Paramagnetic Contrast Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"V08CA06","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Magnetic resonance imaging","category":"indication"},{"label":"Liebel-Flarsheim","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Contrast Media","category":"pharmacology"},{"label":"Diagnostic Uses of Chemicals","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":110.301,"date":"","count":11,"signal":"Gadolinium deposition disease","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=110)"},{"llr":107.16,"date":"","count":16,"signal":"Nephrogenic systemic fibrosis","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=107)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Liebel-Flarsheim","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GADOVERSETAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:41:13.758746+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:41:19.429472+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:41:13.831644+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GADOVERSETAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:41:19.983077+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200457/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:41:20.776896+00:00"}},"allNames":"optimark","offLabel":[],"synonyms":["gadoversetamide","optimark"],"timeline":[{"date":"1999-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from LIEBEL-FLARSHEIM to Liebel-Flarsheim"},{"date":"1999-12-08","type":"positive","source":"DrugCentral","milestone":"FDA approval (Liebel-Flarsheim)"},{"date":"2007-07-23","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Optimark (Gadoveretamide) is a paramagnetic contrast agent developed by Liebel-Flarsheim, used for magnetic resonance imaging (MRI). It is a small molecule modality that was FDA-approved in 1999 for its approved indications. As an off-patent drug with no active Orange Book patents, it is not commercially available as a generic. Optimark is used to enhance the visibility of internal structures during MRI procedures. Key safety considerations include its short half-life of 1.7 hours.","approvals":[{"date":"1999-12-08","orphan":false,"company":"LIEBEL-FLARSHEIM","regulator":"FDA"},{"date":"2007-07-23","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Optimark","ecosystem":[{"indication":"Magnetic resonance imaging","otherDrugs":[{"name":"ferumoxsil","slug":"ferumoxsil","company":"Amag Pharms Inc"},{"name":"gadobutrol","slug":"gadobutrol","company":"Bayer Hlthcare"},{"name":"gadodiamide","slug":"gadodiamide","company":"Ge Healthcare"},{"name":"gadoterate meglumine","slug":"gadoterate-meglumine","company":"Guerbet"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Magnetic Resonance Contrast Activity","modality":"Small Molecule","drugClass":"Paramagnetic Contrast Agent","explanation":"","oneSentence":"","technicalDetail":"Optimark is a gadolinium-based contrast agent that works by shortening the T1 relaxation time of hydrogen nuclei, allowing for improved visualization of internal structures during MRI procedures."},"commercial":{"launchDate":"1999","_launchSource":"DrugCentral (FDA 1999-12-08, LIEBEL-FLARSHEIM)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4147","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=GADOVERSETAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GADOVERSETAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:38:52.645360","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:22.442028+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"gadopentetate dimeglumine","drugSlug":"gadopentetate-dimeglumine","fdaApproval":"1988-06-02","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadodiamide","drugSlug":"gadodiamide","fdaApproval":"1993-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadoteridol","drugSlug":"gadoteridol","fdaApproval":"1992-11-16","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mangafodipir","drugSlug":"mangafodipir","fdaApproval":"1997-11-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadobutrol","drugSlug":"gadobutrol","fdaApproval":"2011-03-14","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gadofosveset","drugSlug":"gadofosveset","fdaApproval":"2008-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"gadopiclenol","drugSlug":"gadopiclenol","fdaApproval":"2022-09-21","patentExpiry":"Sep 19, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"gadoversetamide","indications":{"approved":[{"name":"Magnetic resonance imaging","source":"DrugCentral","snomedId":113091000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Liebel-Flarsheim","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"gadopentetate-dimeglumine","brandName":"gadopentetate dimeglumine","genericName":"gadopentetate dimeglumine","approvalYear":"1988","relationship":"same-class"},{"drugId":"gadodiamide","brandName":"gadodiamide","genericName":"gadodiamide","approvalYear":"1993","relationship":"same-class"},{"drugId":"gadoteridol","brandName":"gadoteridol","genericName":"gadoteridol","approvalYear":"1992","relationship":"same-class"},{"drugId":"mangafodipir","brandName":"mangafodipir","genericName":"mangafodipir","approvalYear":"1997","relationship":"same-class"},{"drugId":"gadobutrol","brandName":"gadobutrol","genericName":"gadobutrol","approvalYear":"2011","relationship":"same-class"},{"drugId":"gadofosveset","brandName":"gadofosveset","genericName":"gadofosveset","approvalYear":"2008","relationship":"same-class"},{"drugId":"gadopiclenol","brandName":"gadopiclenol","genericName":"gadopiclenol","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01986868","phase":"NA","title":"Identification of Adverse Plaque Characteristics by Coronary MR Angiography","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-04","conditions":["Coronary Artery Disease"],"enrollment":2,"completionDate":"2018-01-24"},{"nctId":"NCT01949844","phase":"NA","title":"Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies","status":"COMPLETED","sponsor":"Daniel S. Berman","startDate":"2014-05-16","conditions":["Coronary Artery Disease","CAD"],"enrollment":44,"completionDate":"2017-10-23"},{"nctId":"NCT02092428","phase":"PHASE1","title":"Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-04","conditions":["Coronary Artery Disease"],"enrollment":333,"completionDate":"2017-03-01"},{"nctId":"NCT00811863","phase":"","title":"Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection","status":"WITHDRAWN","sponsor":"Guerbet","startDate":"2009-02","conditions":["Nephrogenic Systemic Fibrosis","Renal Insufficiency"],"enrollment":0,"completionDate":"2012-05-17"},{"nctId":"NCT01092754","phase":"PHASE4","title":"Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients","status":"COMPLETED","sponsor":"Guerbet","startDate":"2002-05","conditions":["Pathological Processes"],"enrollment":100,"completionDate":"2003-12"},{"nctId":"NCT00862459","phase":"PHASE2","title":"Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-08","conditions":["Brain Diseases","Spinal Cord Diseases"],"enrollment":237,"completionDate":"2007-03"}],"_emaApprovals":[{"date":"2007-07-23","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000148663","MMSL":"31825","NDDF":"009502","UNII":"RLM74T3Z9D","VUID":"4021217","CHEBI":"CHEBI:31644","VANDF":"4021217","INN_ID":"7261","RXNORM":"228833","UMLSCUI":"C0754820","chemblId":"CHEMBL1200457","ChEMBL_ID":"CHEMBL1200457","KEGG_DRUG":"D01646","DRUGBANK_ID":"DB00538","PUBCHEM_CID":"444013","SNOMEDCT_US":"409476008","MESH_SUPPLEMENTAL_RECORD_UI":"C112666"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1999-","companyName":"Liebel-Flarsheim","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.7 hours","clearance":"1.2 mL/min/kg","fractionUnbound":"1.0%","volumeOfDistribution":"0.16 L/kg"},"publicationCount":64,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"V08CA06","allCodes":["V08CA06"]},"biosimilarFilings":[],"originalDeveloper":"Liebel-Flarsheim","recentPublications":[{"date":"2006","pmid":"30000471","title":"Gadoversetamide.","journal":""},{"date":"2024 Aug 13","pmid":"39135199","title":"Differences in hypersensitivity reactions and gadolinium deposition disease/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS.","journal":"BMC medicine"},{"date":"2024 Apr 1","pmid":"38244800","title":"Drug-induced depressive symptoms: An update through the WHO pharmacovigilance database.","journal":"Journal of affective disorders"},{"date":"2024 Mar","pmid":"37991701","title":"Gold nanoparticles conjugated with epidermal growth factor and gadolinium for precision delivery of contrast agents in magnetic resonance imaging.","journal":"Radiological physics and technology"},{"date":"2022 Nov","pmid":"35184618","title":"Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes in vitro.","journal":"Drug and chemical toxicology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Liebel-Flarsheim","companyId":"liebel-flarsheim","modality":"Small molecule","firstApprovalDate":"1999","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":""},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1999-12-08T00:00:00.000Z","mah":"LIEBEL-FLARSHEIM","brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:41:22.442028+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}